Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2019

Open Access 01-12-2019 | EBM | Research

Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck

Authors: A D Jensen, Jürgen Debus

Published in: Radiation Oncology | Issue 1/2019

Login to get access

Abstract

Background

Particle therapy provides steep dose gradients to facilitate dose escalation in challenging anatomical sites which has been shown not only to improve local control but also overall survival in patients with ACC. Cost-effectiveness of intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost vs IMRT alone was performed in order to objectivise and substantiate more widespread use of this technology in ACC.

Methods

Patients with pathologically confirmed ACC received a combination regimen of IMRT plus C12 boost. Patients presenting outside C12 treatment slots received IMRT only. Clinical results were published; economic analysis on patient-level data was carried out from a healthcare purchaser’s perspective based on costs of healthcare utilization. Cost histories were generated from resource use recorded in individual patient charts and adjusted for censoring using the Lin I method. Cost-effectiveness was measured as incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed regarding potentially differing management of recurrent disease.

Results

The experimental treatment increased overall costs by € 18,076 (€13,416 – €22,922) at a mean survival benefit of 0.86 years. Despite improved local control, following costs were also increased in the experimental treatment. The ICER was estimated to 26,863 €/LY. After accounting for different management of recurrent disease in the two cohorts, the ICER was calculated to 20,638 €/LY.

Conclusion

The combined treatment (IMRT+C12 boost) substantially increased initial and overall treatment cost. In view of limited treatment options in ACC, costs may be acceptable though. Investigations into quality of life measures may support further decisions in the future.
Literature
1.
Lievens Y, Pijls-Johannesma M. Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol. 2013;23(2):134–41.CrossRef
2.
Peeters A, Grutters JP, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, Joore MA, Lambin P. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95(1):45–53.CrossRef
3.
Vanderstraeten B, Verstraete J, De Croock R, De Neve W, Lievens Y. In search of the economic sustainability of hadron therapy: the real cost of setting up and operating a hadron facility. Int J Radiat Oncol Biol Phys. 2014;89(1):152–60.CrossRef
4.
Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol). 2003;15(1):S37–50.CrossRef
5.
Mizoe JE, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T, Tonoki M, Tsuji H, Kamada T, Tsujii H, Okamoto Y. Organizing Committee for the Working Group for Head neck Cancer. Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 2012;103(1):32–7.CrossRef
6.
Mizoe JE, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, Hasegawa A, Yamamoto N, Ebihara S, Konno A. Organizing committee for the working group for head-and-neck cancer. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;60(2):358–64.CrossRef
7.
Schulz-Ertner D, Nikoghosyan A, Didinger B, Münter M, Jäkel O, Karger CP, Debus J. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005;104(2):338–44.CrossRef
8.
Münter MW, Schulz-Ertner D, Hof H, Nikoghosyan A, Jensen A, Nill S, Huber P, Debus J. Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: initial clinical results and toxicity of treatment. Radiat Oncol. 2006;1:17.CrossRef
9.
Chen AM, Bucci MK, Weinberg V, Garcia J, Quivey JM, Schechter NR, Phillips TL, Fu KK, Eisele DW. Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys. 2006;66:152–9.CrossRef
10.
Terhaard CHJ, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, Tjho-Heslinga RE, de Jong JM, Roodenburg JL, Head D, Neck Oncology Cooperative Group. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26:681–92.CrossRef
11.
Terhaard CHJ, Lubsen H, Rasch CRN, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van Den Ende PL, Burlage F, Head D, Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005;61:103–11.CrossRef
12.
Garden AS, Weber RS, Ang KK, Morrison WH, Matre J, Peters LJ. Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer. 1994;73(10):2563–9.CrossRef
13.
Jensen AD, Nikoghosyan AV, Poulakis M, Höss A, Haberer T, Jäkel O, Münter MW, Schulz-Ertner D, Huber PE, Debus J. Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival. Cancer. 2015;121(17):3001–9.CrossRef
14.
Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8:177–84.CrossRef
15.
Jensen AD, Nikoghosyan A, Windemuth-Kieselbach C, Debus J, Münter MW. Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC. BMC Cancer. 2010;10:546.CrossRef
16.
17.
Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60(12):2869–72.CrossRef
18.
19.
20.
21.
22.
23.
Personal communication. Carbon ion therapy reimbursement rates. Betriebskrankenkassen (BKK) email correspondence of 08 June 2015.
24.
25.
Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53:419–34.CrossRef
26.
27.
28.
Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med. 1996;15(13):1447–58.CrossRef
29.
Fieller EC. Some problems in interval estimation. JR Stat Soc Ser B. 1954;16:175–85.
30.
Gray A, Clarke P, Wolstenholme J, Wordsworth S. Handbooks in health economic evaluation series. In: Applied methods of cost-effectiveness analysis in healthcare: Oxford University Press; 2011. Supporting material via https://​www.​herc.​ox.​ac.​uk/​downloads/​supporting-material-for-applied-methods-of-cost-effectiveness-analysis-in-healthcare , last accessed 20.08.2016.
31.
32.
33.
Newhouse JP. Medical care costs: how much welfare loss? J Econ Perspect. 1992;6(3):3–21.CrossRef
34.
Di Matteo L. The macro determinants of health expenditure in the United States and Canada: assessing the impact of income, age distribution and time. Health Policy. 2005;71(1):23–42.CrossRef
35.
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105(1):25–32.CrossRef
36.
Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44(8):850–61 PubMed PMID: 16332592.CrossRef
37.
Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer. 2005;103(4):793–801.CrossRef
38.
Cheng Q, Roelofs E, Ramaekers BL, Eekers D, van Soest J, Lustberg T, Hendriks T, Hoebers F, van der Laan HP, Korevaar EW, Dekker A, Langendijk JA, Lambin P. Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - comparison of dose, toxicity and cost-effectiveness. Radiother Oncol. 2016;118(2):281–5.CrossRef
39.
Ramaekers BL, Grutters JP, Pijls-Johannesma M, Lambin P, Joore MA, Langendijk JA. Protons in head-and-neck cancer: bridging the gap of evidence. Int J Radiat Oncol Biol Phys. 2013;85(5):1282–8.CrossRef
40.
van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist. 2011;16(3):366–77.CrossRef
41.
Jäkel O, Land B, Combs SE, Schulz-Ertner D, Debus J. On the cost-effectiveness of carbon ion radiation therapy for skull base chordoma. Radiother Oncol. 2007;83(2):133–8.CrossRef
42.
Jensen AD, Poulakis M, Nikoghosyan AV, Chaudhri N, Uhl M, Münter MW, Herfarth KK, Debus J. Re-irradiation of adenoid cystic carcinoma: analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiother Oncol. 2015;114(2):182–8.CrossRef
43.
44.
45.
Lauterbach KW, Schwartz FW, Potthoff P, Schmitz H, Lüngen M, Krauth C, Klostermann B, Gerhardus A, Stock S, Steinbach T, Müller U, Brandes I. Bestandsaufnahme der Rolle von Ambulanzen der Hochschulkliniken in Forschung, Lehre und Versorgung an ausgewählten Standorten (Hochschulambulanzenstudie). Ein Gutachten im Auftrag des Bundesministeriums für Bildung und Forschung (BMBF) via http://​www.​gesundheitsforsc​hung-bmbf.​de/​_​media/​Gutachten_​Ambulanzen_​26.​pdf, accessed 28 Aug 2015.
46.
Lüngen M, Stock S, Krauth C, Gerhardus A, Brandes I, Potthoff P, Müller U, Schmitz H, Klostermann B, Steinbach T, Schwartz FW, Lauterbach KW. Performance and costs of outpatient clinics of university hospitals for medical care, teaching, research activities. Dtsch Med Wochenschr. 2004;129(45):2399–404.CrossRef
Metadata
Title
Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck
Authors
A D Jensen
Jürgen Debus
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2019
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-019-1395-9

Other articles of this Issue 1/2019

Radiation Oncology 1/2019 Go to the issue

Research

Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia - dosimetry comparison of different regimens and clinical application

Research

Effect of changes in monitor unit rate and energy on dose rate of total marrow irradiation based on Linac volumetric arc therapy

Study protocol

Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)

Research

Dosimetric impact of intrafraction motion on boosts on intraprostatic lesions: a simulation based on actual motion data from real time ultrasound tracking

Research

Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma

Research

Analyses of the factors influencing the accuracy of three-dimensional ultrasound in comparison with cone-beam CT in image-guided radiotherapy for prostate cancer with or without pelvic lymph node irradiation